Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
- Strong cash position of $697.9M providing runway through 2028
- Positive Phase 3 VERIFY trial results for rusfertide in polycythemia vera
- Positive Phase 2b ANTHEM trial results for icotrokinra in ulcerative colitis
- Both lead assets progressing to NDA filings by year end
- Earned $25M milestone payment in Q1 2025
- Net loss of $11.7M in Q1 2025 compared to net income of $207.3M in Q1 2024
- Significant decrease in license and collaboration revenue to $28.3M from $255.0M year-over-year
- Increased R&D expenses to $35.9M from $33.7M in previous year
Insights
Protagonist reports successful Phase 3 rusfertide and Phase 2b icotrokinra trials, advancing both drugs to NDA filings with $697.9M cash runway through 2028.
Protagonist's Q1 results showcase exceptional clinical progress that meaningfully derisks their portfolio. Rusfertide's Phase 3 VERIFY trial in polycythemia vera achieved statistical significance (p<0.0001) for its primary endpoint of clinical response, alongside meeting all four key secondary endpoints. Selection for ASCO's prestigious plenary session signifies these results are viewed as practice-changing by the oncology community - a rare honor reserved for the most impactful clinical advances.
Simultaneously, icotrokinra (JNJ-2113) delivered positive Phase 2b ANTHEM results in ulcerative colitis, expanding beyond its successful Phase 3 psoriasis program where data was presented at major dermatology conferences. The parallel advancement of both assets toward NDA submissions by year-end represents an unusual achievement for a biotech of this size.
The company's pipeline diversification strategy is progressing with preclinical candidates including oral IL-17 antagonist PN-881 entering clinical development this year, plus emerging programs in obesity and hepcidin modulation. This multi-therapeutic approach across hematology, immunology, and metabolic diseases creates multiple independent value-creation pathways, substantially reducing the binary risk typical of single-asset developers.
Protagonist maintains an exceptionally strong balance sheet with
Q1 revenue of
The current quarter's net loss of
With two partnered assets advancing toward commercialization and substantial milestone potential ahead, Protagonist has effectively transformed its financial risk profile. The company can now progress its wholly-owned early pipeline candidates without dilutive financing concerns, creating an asymmetric risk-reward profile rarely seen among development-stage biotechs.
Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st
Conference call to be held June 2nd at 8AM EDT to discuss rusfertide data presented at ASCO
Full dataset from Phase 3 ICONIC-LEAD trial with icotrokinra in patients with moderate-to-severe plaque psoriasis (PsO) presented at the 2025 AAD Meeting in March; data from adolescent subset presented at World Congress of Pediatric Dermatology in April
Positive top line results from icotrokinra Phase 2b ANTHEM trial in moderately to severely active ulcerative colitis (UC) announced in March, data to be presented at medical conference later in 2025
Cash, cash equivalents and marketable securities of
NEWARK, CALIFORNIA / ACCESS Newswire / May 6, 2025 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.
"Protagonist is off to a very strong 2025 with multiple transformational events in the first quarter for our two late-stage partnered assets, rusfertide and icotrokinra which are progressing to NDA filings by year end," said Dinesh V. Patel, Ph.D., the Company's President and CEO. "We look forward to presenting data from rusfertide's Phase 3 VERIFY study at a plenary session at ASCO on June 1st. We're very pleased with the highly positive results from the icotrokinra Phase 2b ANTHEM study in ulcerative colitis which lay the foundation for additional studies in both UC and Crohn's. We are continuing to increasingly focus on advancement of our pre-clinical candidates including the oral IL-17 antagonist PN-881, as well as additional candidates emerging from our oral anti-obesity and oral hepcidin programs. We are fortunate to be in a very strong cash position, allowing us to independently and rapidly progress our early-stage pipeline into value-creating clinical safety and proof-of-concept studies starting with PN-881 in 2025."
First Quarter 2025 Recent Developments and Upcoming Milestones
Rusfertide: Subcutaneous Injectable Hepcidin Mimetic for Polycythemia Vera (PV) and Other Blood Disorders
Abstract accepted for presentation at the Plenary Session at the 2025 American Society of Clinical Oncology (ASCO).
Data from the Phase 3 VERIFY trial of rusfertide in PV has been accepted for a prestigious oral presentation during the plenary session on Sunday, June 1 at 2:09PM CDT at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
The Company will host an investor conference call Monday, June 2, 2025, at 8AM EDT to discuss data shared during the plenary presentation:
Conference Call and Webcast Details
US-based Investors: 1-877-300-8521
International Investors:1-412-317-6026
Conference Call ID: 10199589
The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1718556&tp_key=360d3b714d
A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event.
On March 3rd, the Company announced positive topline results from the Phase 3 VERIFY study. Key findings include:
Study met primary endpoint with a significantly higher proportion of clinical responders[1] on rusfertide compared to placebo during weeks 20-32 (p<0.0001)
Study met all four key secondary endpoints (weeks 0-32)
Phlebotomy rate - EU primary endpoint (p<0.0001)
Hematocrit control
Patient-reported outcomes of PROMIS Fatigue and MFSAF TSS-7
Safety profile consistent with previous rusfertide studies, with no new safety signals
Icotrokinra (JNJ-2113): Oral IL-23 Receptor Antagonist
On April 10th, data from the adolescent cohort of the Phase 3 ICONIC-LEAD study in moderate-to-severe plaque psoriasis was presented as a late-breaking abstract at the 2025 World Congress of Pediatric Dermatology (WCPD).
On March 10th, positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra in adults with moderately to severely active ulcerative colitis (UC) were announced. The full data set is expected at a medical conference later this year.
On March 8th, data from the adult cohort of the Phase 3 ICONIC-LEAD study in moderate-to-severe plaque psoriasis were presented as a late-breaking abstract at the 2025 American Academy of Dermatology (AAD) Annual Meeting.
First Quarter 2025 Financial Results
Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of March 31, 2025, were
$697.9 million as compared to$559.2 million as of December 31, 2024.
Three Months Ended | ||||||||
March 31, | ||||||||
(in thousands, except per share amounts) | 2025 | 2024 | ||||||
(Unaudited) | ||||||||
License and collaboration revenue | $ | 28,321 | $ | 254,953 | ||||
Research and development expense | $ | 35,893 | $ | 33,734 | ||||
General and administrative expense | $ | 11,738 | $ | 14,910 | ||||
Income tax expense | $ | -- | $ | 3,326 | ||||
Net (loss) income | $ | (11,655 | ) | $ | 207,340 | |||
Basic (loss) earnings per share | $ | (0.19) | $ | 3.41 | ||||
Diluted (loss) earnings per share | $ | (0.19) | $ | 3.26 | ||||
License and Collaboration Revenue: License and collaboration revenue of
$28.3 million for the period ended March 31, 2025, consisted of: (i)$22.8 million related to proportional recognition of the$25 million milestone earned in Q1 2025 but payable following completion of the VERIFY clinical study report, and (ii)$5.5 million allocated to development services provided by us under the agreement during the period. License and collaboration revenue of$255.0 million for the period ended March 31, 2024 consisted of: (i)$254.1 million of the$300.0 million transaction price for the Takeda Collaboration Agreement allocated to the rusfertide license delivered to Takeda upon effectiveness of the agreement on March 15, 2024, and (ii)$0.9 million allocated to development services provided by us under the agreement during the last two weeks of March 2024.
Research and Development ("R&D") Expenses: The increase in R&D expenses from the prior year period was primarily due to an increase in pre-clinical and drug discovery research expenses, partially offset by a decrease in rusfertide expenses related to the Phase 3 VERIFY clinical trial.
General and Administrative ("G&A") Expenses: The decrease in G&A expenses from the prior year period was primarily due to
$4.6 million in advisory and legal fees related to the Takeda collaboration, partially offset by an increase in stock-based compensation expense.
Income Tax Expense: Income tax expense of
$3.3 million for the period ended March 31, 2024, consisted of tax related to the upfront payment earned under the Takeda collaboration agreement.
Net (Loss) Income: Net loss was
$11.7 million , or$0.19 per basic and diluted share, for the first quarter of 2025 as compared to net income of$207.3 million , or$3.41 per basic share and$3.26 per diluted share, for the first quarter of 2024.
[1] A responder is a patient who completed weeks 0-32 of the study, was not phlebotomy eligible and did not receive a phlebotomy during weeks 20-32. To meet phlebotomy eligibility, patients in the study were required to have: confirmed hematocrit ≥
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") which is licensed to J&J Innovative Medicines ("JNJ"), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, oral hepcidin program, and oral obesity program.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of icotrokinra and rusfertide, the timing of icotrokinra and rusfertide clinical trials, and timing of developments and announcements in our discovery programs. In some cases, you can identify these statements by forward-looking words such as "anticipate," "believe," "may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk Factors" contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577
Media Relations Contact
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext 1
PROTAGONIST THERAPEUTICS, INC.
Condensed Consolidated Statements of Operations
(Unaudited)
(Amounts in thousands except share and per share data)
Three Months Ended | ||||||||
March 31, | ||||||||
2025 | 2024 | |||||||
License and collaboration revenue | $ | 28,321 | $ | 254,953 | ||||
Operating expense: | ||||||||
Research and development (1) | 35,893 | 33,734 | ||||||
General and administrative (1) | 11,738 | 14,910 | ||||||
Total operating expense | 47,631 | 48,644 | ||||||
(Loss) income from operations | (19,310 | ) | 206,309 | |||||
Interest income | 7,573 | 4,376 | ||||||
Other income (expense), net | 82 | (19 | ) | |||||
(Loss) income before income tax expense | (11,655 | ) | 210,666 | |||||
Income tax expense | - | 3,326 | ||||||
Net (loss) income | $ | (11,655 | ) | $ | 207,340 | |||
Net (loss) income per share, basic | $ | (0.19 | ) | $ | 3.41 | |||
Net (loss) income per share, diluted | $ | (0.19 | ) | $ | 3.26 | |||
Weighted-average shares used to compute net (loss) income per share, basic | 62,963,806 | 60,855,689 | ||||||
Weighted-average shares used to compute net (loss) income per share, diluted | 62,963,806 | 63,595,328 | ||||||
(1) Amount includes non-cash stock-based compensation expense.
Stock-based Compensation
(Unaudited, in thousands)
Three Months Ended | ||||||||
March 31, | ||||||||
2025 | 2024 | |||||||
Research and development | $ | 7,991 | $ | 5,288 | ||||
General and administrative | 5,811 | 4,064 | ||||||
Total stock-based compensation expense | $ | 13,802 | $ | 9,352 | ||||
PROTAGONIST THERAPEUTICS, INC.
Selected Condensed Consolidated Balance Sheet Data
(Unaudited, In thousands)
March 31, | December 31, | |||||||
2025 | 2024 | |||||||
Cash, cash equivalents and marketable securities | $ | 697,877 | $ | 559,165 | ||||
Working capital | 570,748 | 544,243 | ||||||
Total assets | 742,132 | 744,725 | ||||||
Deferred revenue | 25,071 | 30,567 | ||||||
Accumulated deficit | (352,177 | ) | (340,522 | ) | ||||
Total stockholders' equity | 689,052 | 675,295 | ||||||
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire
FAQ
What were the key financial results for Protagonist Therapeutics (PTGX) in Q1 2025?
What were the main clinical trial results announced by PTGX in Q1 2025?
When will PTGX present the Phase 3 VERIFY trial results for rusfertide?
What is the status of PTGX's drug pipeline development?
Why did PTGX's revenue decrease significantly in Q1 2025 compared to Q1 2024?
